Such vulnerability of ATM-AVI could also compromise the combined effectiveness of CAZ-AVI and ATM (both targeting PBP3), being viewed as a “rescue therapy” for serious MBL-producer infections (43, 44). The gene discussed is ATM; the disease is infection.